Skip Navigation

Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more

Key Eligibility Criteria for CAR T-Cell Therapy for Lymphoma

  • Patients who meet the following eligibility criteria may be appropriate for CAR T-cell therapy:

    • Confirmed diagnosis of DLBCL, primary mediastinal large B cell lymphoma, high grade B-cell lymphoma, or transformed follicular lymphoma to DLBCL that has relapsed or not responded to at least two prior lines of systemic therapy. (CAR T products: Yescarta, KYMRIAH®, Breyanzi)
    • Confirmed diagnosis of follicular lymphoma that has relapsed or not responded after two prior lines of treatment. (CAR T product: Yescarta)
    • Confirmed diagnosis of mantle cell lymphoma that has either not responded to, or relapsed after first line of therapy (CAR T product: Tecartus)

  • Caron Jacobson, MD, at a computer

    Caron Jacobson, MD, is involved in clinical trials of CAR T-cell therapies for patients with a type of lymphoma.

  • Dana-Farber Brigham Cancer Center logo
  • Contact Information for CAR T-Cell Therapy

    For more information about CAR T-cell therapy, please call 877-801-CART (2278).

  • Pediatric CAR T-Cell Therapy

    Dana-Farber/Boston Children's is a certified treatment center for providing the recently FDA-approved CAR T-cell therapy called KYMRIAH® to patients who are up to 25 years old with second or later relapsed or refractory B-cell acute lymphoblastic leukemia (ALL).